This provides a theoretical basis for the development of combined therapeutic strategies for tumor metabolic heterogeneity, especially for tumor subtypes with high mitochondrial respiratory activity: targeting TfR1 may produce more precise therapeutic effects. This evidence concerns the gene TFRC and neoplasm.